Key clinical point: Multigene panel sequencing is moderately cost-effective in patients with advanced NSCLC.

Major finding: Compared with single-marker genetic testing, multigene panel sequencing had an incremental cost-effectiveness ratio of $148,478 per life-year gained.

Study details: Retrospective cohort study of 5,688 patients with advanced NSCLC from a large nationwide database.

Disclosures: Dr. Steuten disclosed having a consulting or advisory role with Agendia and Roche (immediate family member), and receiving research funding from Thermo Fisher Scientific, EMD Serono (institutional), Nohla Therapeutics (institutional), and the Personalized Medicine Coalition (institutional), which funded the study.